Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors

被引：0
|
作者：
Spoerke, Jill [1 ]
Desai, Rupal [1 ]
Patel, Rajesh [1 ]
Fredrickson, Jill [1 ]
Wang, Yulei [1 ]
Levy, Gallia [1 ]
Gendreau, Steve [1 ]
Lauchle, Jennifer [1 ]
Derynck, Mika [1 ]
Raja, Rajiv [1 ]
Koeppen, Hartmut [1 ]
Hampton, Garret [1 ]
Yan, Yibing [1 ]
Lackner, Mark R. [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-4567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4567
引用
收藏
页数：1
相关论文
共 50 条
  • [41] REDUCED CANCER CELL SENSITIVITY TO TUMOR TREATING FIELDS (TTFIELDS) THROUGH ACTIVATION OF THE PI3K/AKT/MTOR SIGNALING PATHWAY CAN BE MITIGATED USING PI3K INHIBITORS OR PI3K/MTOR DUAL INHIBITORS
    Klein-Goldberg, Anat
    Voloshin, Tali
    Zemer-Tov, Efrat
    Paz, Rom
    Koren, Lilach
    Wainer-Katsir, Kerem
    Volodin, Alexandra
    Koltun, Bella
    Brant, Boris
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2021, 23 : 84 - 84
  • [42] Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors
    Juric, Dejan
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 765 - 766
  • [43] Development of PI3Kγ selective inhibitors: the strategies and application
    Gu, Dong-Yan
    Zhang, Meng-Meng
    Li, Jia
    Zhou, Yu-Bo
    Sheng, Rong
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (02) : 238 - 247
  • [44] Selective PI3Kδ inhibitors, a review of the patent literature
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (11) : 1773 - 1790
  • [45] Development of novel, selective and irreversible PI3Kδ inhibitors
    Dalton, Samuel
    Campos, Sebastien
    Bush, Jacob
    Thomas, Daniel
    Convery, Maire
    Murphy, John
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [46] Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors
    Methot, Joey L.
    Achab, Abdelghani
    Christopher, Matthew
    Zhou, Hua
    McGowan, Meredeth A.
    Trotter, B. Wesley
    Fradera, Xavier
    Lesburg, Charles A.
    Goldenblatt, Peter
    Hill, Armetta
    Chen, Dapeng
    Otte, Karin M.
    Augustin, Martin
    Shah, Sanjiv
    Katz, Jason D.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (12): : 2461 - 2469
  • [47] PI3K Isoform-Selective Inhibitors in Cancer
    Duncan, Leslie
    Shay, Chloe
    Teng, Yong
    SINGLE-CELL SEQUENCING AND METHYLATION: METHODS AND CLINICAL APPLICATIONS, 2020, 1255 : 165 - 173
  • [48] PI3K AND/OR MTOR INHIBITORS: CURRENT STATUS, FUTURE DIRECTIONS
    Loi, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 59 - 59
  • [49] PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
    Alzahrani, Ali S.
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 125 - 132
  • [50] Identification of highly potent and selective PI3Kδ inhibitors
    Marcoux, David
    Quin, Lan-Ying
    Ruan, Zheming
    Shi, Qing
    Ruan, Qian
    Weigelt, Carolyn
    Qiu, Hongchen
    Schieven, Gary
    Hynes, John
    Bhide, Rajeev
    Poss, Michael
    Tino, Joseph
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (13) : 2849 - 2853
12345